Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease

Lupus

Volumn 9, Issue 6, 2000, Pages 413-416

  Tam, L S ^a   Li, E K ^a   Lam, C W K ^a   Tomlinson, B ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Fasting lipids; Hydroxychloroquine; Systemic lupus erythematosus

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIET RESTRICTION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033944464     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120300678828541     Document Type: Article

References (21)

1. Urowitz MB. Bookman AAM, Koehler BE et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.
2. Wallace DJ, Metzger AL, Stecher VJ et al. Cholesterol-lowering effects of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322-326.
3. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96: 254-259.
4. Rahman P, Gladman DD, Urowitz MB et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999; 26: 325-330.
5. Nossen JO, Rustan AC, Barnard T, Drevon CA. Inhibition of chloroquine of the secretion of very low density lipoproteins by cultured rat hepatocytes. Biochim Biophys Acta 1984; 803: 11-20.
6. Chen HW, Leonard DA. Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells. J Biol Chem 1984; 259: 8156-8162.
7. Goldstein JL, Brunschede GY, Brown MS. Inhibition of proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339. J Biol Chem 1975; 250: 7854-7862.
8. Powrie JK, Shojaee-Moradie F, Watts GF et al. Effects of chloroquine on the dyslipidaemia of non-insulin-dependent diabetes mellitus. Metabolism 1993; 42: 415-419.
9. Hodis HN, Quismorio FP Jr, Wickham E, Blankenhorn DH. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993; 20: 661-665.
10. Ettinger WH, Goldberg AP, Appelbaum-Bowden D, Hazzard WR. Dyslipoproteinaemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987; 83: 503-508.
11. Borba EF, Bonfa E. Dyslipoproteinaemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 533-539.
12. Borba EF, Santos RD, Bonfa E et al. Eipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 1994; 21: 220-223.
13. Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991; 115: 209-218.
14. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10: 240-245.
15. Kawai S, Mizushima Y, Kaburaki J. Increased serum lipoprotein(a) levels in systemic lupus erythematosus with myocardial and cerebral infarction. J Rheumatol 1995; 22: 1210-1211 (letter).
16. Atsumi T, Khamashta MA, Andujar C et al. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol 1998; 25: 69-73.
17. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the plasma low density lipoprotein cholesterol concentration without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-512.
19. Kurzrock R, Rohde MF, Quesada JR et al. Recombinant gamma-interferon induced hypertriglyceridaemia and inhibits post-heparin lipase activity in cancer patients. J Exp Med 1986; 164: 1093-1101.
20. Beutler BA, Cerami A. Recombinant interleukin-1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 1985; 135: 3969-3971.
21. Ettinger WH, Hazzard WR. Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism 1988; 37: 1055-1058.